Intellia Therapeutics and SparingVision Strategic Collaboration to Develop Novel Ocular Therapies. See Also: Crispr Therapeutics’ News is Good, Not Bad
October 14, 2021
0
Intellia Therapeutics and SparingVision Collaboration Intellia Therapeutics (NTLA) and SparingVision - a genomic medicine company developing vision saving treatments for ocular diseases, announced a strategic collaboration to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. Intellia Therapeutics is to grant SparingVision exclusive rights to Intellia . . . This content is for paid subscribers. Please click here to subscribe or here to …